These links are provided as a convenience and is not an endorsement by Allena Pharmaceuticals of the site's content. Allena does not review or control the content of non-Allena websites.
Recently Added - ASN 2020
Establishing Safety and Efficacy of Reloxaliase in Patients with Enteric Hyperoxaluria (URIROX-2). Kausz AT et al. Kidney Week 2020.
Safety and Efficacy of Reloxaliase in Enteric Hyperoxaluria (EH): An Aggregate Review of Completed Studies. Wyatt CM et al. Kidney Week 2020.
Pharmacodynamic (PD) Profiling of Reloxaliase in Patients with Severe Hyperoxaluria. Knauf F et al. Kidney Week 2020
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria (URIROX-2): A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study. Kausz AT et al. Kidney Week 2019.
A Phase 3, Randomized, Placebo-Controlled Trial of Reloxaliase in Enteric Hyperoxaluria (URIROX-1): Clinical Characteristics and Burden of Illness. Lieske JC et al. Kidney Week 2019.
Pilot Study of Reloxaliase in Patients with Severe Enteric Hyperoxaluria and Hyperoxalemia: A Pro Tem Analysis of Study ALLN-177-206. Knauf F et al. Kidney Week 2019.
Dietary Oxalate Ingestion, Urinary Oxalate Levels, and Response to Reloxaliase in Three Phase II Studies. Langman CB et al. Kidney Week 2019.
Prevalence of Kidney Stones in Patients With Enteric Disorders. Tasian GE et al. Kidney Week 2019.
Case Series of First Four Subjects with EH and Advanced CKD Treated with Reloxaliase. OHF International Hyperoxaluria Workshop 2019
Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria (uriROX-1). Nigewar S et al. ASN Kidney Week 2018.
Results of a Phase 2 Randomized Controlled Trial of ALLN-177 in Patients wth Secondary Hyperoxaluria. Nigwekar S. ASN Kidney Week 2017.
ALLN-177, a Novel Oral Enzyme Therapy, Reduces Urinary Oxalate Excretion and Plasma Oxalate in a Porcine Dietary Model of Severe Hyperoxaluria. Grujic D et al. ASN Kidney Week 2017.
A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme. Langman CB et al. Am J Nephrol 2016.
ALLN-177 Reduces Hyperoxaluria in a Porcine Model of Secondary Hyperoxaluria (2°HO) Induced by a Human-like Oxalate Rich Diet. Grujic D et al. J Urol 2016.
Hyperoxaluria Is Reduced and Nephrocalcinosis Prevented with an Oxalate-Degrading Enzyme in Mice with Hyperoxaluria. Grujic D et al. Am J Nephrol 2009.
A Novel Recombinant Oral Urate Oxidase (UrOx) ALLN-346 Reduces Severe Hyperuricemia and Normalized Hyperuricosuria in Nephropathic UrOX Knockout (UrOxKO) Mice Grujic D et al. ACR 2018
Hypereoxaluria and Kidney Disorders
Unmet Need in Enteric Hyperoxaluria: Clinical Characteristics and Stone Burden in Patients from ALLN-177 Studies. Nigwekar S et al. ASN Kidney Week 2018.
The Cause of Idiopathic Calcium Stone Disease: Hypercalciuria or Hyperoxaluria? Robertson WG, Peacock M. Nephron 1980.
Comparison of Two Diets for the Prevention of Recurrent Stones in Idiopathic Hypercalciuria. Borghi L et al. N Engl J Med 2002.
The Most Important Metabolic Risk Factors in Recurrent Urinary Stone Formers. Parvin M et al. Urol J 2011.
24-h Uric Acid Excretion and the Risk of Kidney Stones. Curhan GC et al. Kidney Int 2008.
Results of Long-term Treatment with Orthophosphate and Pyridoxine in Patients with Primary Hyperoxaluria. Milliner DS et al. N Engl J Med 1994.
Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure. Zhao F et al. Clin J Am Soc Nephrol 2016.
Risk of Nephrolithiasis, Hyperoxaluria, and Calcium Oxalate Supersaturation Increased after Roux-en-Y Gastric Bypass Surgery: A Systematic Review and Meta-analysis. Upala S et al. Surg Obes Relat Dis 2016.
Enteric Hyperoxaluria: An Important Cause of End-stage Kidney Disease. Nazzal L et al. Nephrol Dial Transplant 2016.
Enteric Hyperoxaluria in Chronic Pancreatitis. Demoulin N et al. Medicine 2017.
Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass: An Underrecognized Cause of Irreversible Renal Failure. Nasr S et al. Clin J Am Soc Nephrol 2008.
Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease. Pernipam M et al. Clin Biochem 2017.
Treatment of the Primary Hyperoxalurias: A New Chapter. Milliner, D. Kidney Int 2006.
Primary and Secondary Hyperoxaluria: Understanding the Enigma. Bhasin B et al. World J Nephrol 2015.
Prevalence of Hyperoxaluria in Urinary Stone Formers: Chronological and Geographic Trends and a Literature Review. Spradling K et al. J Endourol 2016.
Oxalate, Inflammasome and Progression of Kidney Disease. Ermer T et al. Curr Opin Nephro Hypertens 2016.